Premature ventricular contraction prevention
|
Premature ventricular contraction Microchapters |
|
Differentiating Premature Ventricular Contraction from other Disorders |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Premature ventricular contraction prevention On the Web |
|
to Hospitals Treating Premature ventricular contraction prevention |
|
Risk calculators and risk factors for Premature ventricular contraction prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Homa Najafi, M.D.[2] Radwa AbdElHaras Mohamed AbouZaied, M.B.B.S[3]
Overview
There are no established measures for the secondary prevention of [disease name].
OR
Effective measures for the secondary prevention of [disease name] include [strategy 1], [strategy 2], and [strategy 3].
Secondary Prevention
There are no established measures for the secondary prevention of [disease name].
OR
Effective measures for the secondary prevention of [disease name] include:
- [Strategy 1]
- [Strategy 2]
- [Strategy 3]
Recommendations for Secondary Prevention of SCD in Patients With Ischemic Heart Disease
| Class I |
| 1. In patients with ischemic heart disease, who either survive SCA due to VT/VF or experience hemodynamically unstable VT (Level of Evidence: B-R)[1][2][3][4] or stable sustained VT (Level of Evidence: B-NR)[5] not due to reversible causes, an ICD is recommended if meaningful survival greater than 1 year is expected.
2. A transvenous ICD provides intermediate value in the secondary prevention of SCD particularly when the patient’s risk of death due to a VA is deemed high and the risk of nonarrhythmic death (either cardiac or noncardiac) is deemed low based on the patient’s burden of comorbidities and functional status (Level of Evidence: B-R).[6] 3. In patients with ischemic heart disease and unexplained syncope who have inducible sustained monomorphic VT on electrophysiological study, an ICD is recommended if meaningful survival of greater than 1 year is expected (Level of Evidence: B-NR).[7]
|
References
- ↑ "A Comparison of Antiarrhythmic-Drug Therapy with Implantable Defibrillators in Patients Resuscitated from Near-Fatal Ventricular Arrhythmias". New England Journal of Medicine. 337 (22): 1576–1584. 1997. doi:10.1056/NEJM199711273372202. ISSN 0028-4793.
- ↑ Connolly, Stuart J.; Gent, Michael; Roberts, Robin S.; Dorian, Paul; Roy, Denis; Sheldon, Robert S.; Mitchell, L. Brent; Green, Martin S.; Klein, George J.; O’Brien, Bernard (2000). "Canadian Implantable Defibrillator Study (CIDS)". Circulation. 101 (11): 1297–1302. doi:10.1161/01.CIR.101.11.1297. ISSN 0009-7322.
- ↑ Connolly, S (2000). "Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials". European Heart Journal. 21 (24): 2071–2078. doi:10.1053/euhj.2000.2476. ISSN 0195-668X.
- ↑ Kuck, Karl-Heinz; Cappato, Riccardo; Siebels, Jürgen; Rüppel, Rudolf (2000). "Randomized Comparison of Antiarrhythmic Drug Therapy With Implantable Defibrillators in Patients Resuscitated From Cardiac Arrest". Circulation. 102 (7): 748–754. doi:10.1161/01.CIR.102.7.748. ISSN 0009-7322.
- ↑ Raitt, Merritt H.; Renfroe, Ellen Graham; Epstein, Andrew E.; McAnulty, John H.; Mounsey, Paul; Steinberg, Jonathan S.; Lancaster, Scott E.; Jadonath, Ram L.; Hallstrom, Alfred P. (2001). ""Stable" Ventricular Tachycardia Is Not a Benign Rhythm". Circulation. 103 (2): 244–252. doi:10.1161/01.CIR.103.2.244. ISSN 0009-7322.
- ↑ Owens, Douglas K.; Sanders, Gillian D.; Heidenreich, Paul A.; McDonald, Kathryn M.; Hlatky, Mark A. (2002). "Effect of risk stratification on cost-effectiveness of the implantable cardioverter defibrillator". American Heart Journal. 144 (3): 440–448. doi:10.1067/mhj.2002.125501. ISSN 0002-8703.
- ↑ Bass, Eric B.; Elson, James J.; Fogoros, Richard N.; Peterson, Jacqueline; Arena, Vincent C.; Kapoor, Wishwa N. (1988). "Long-term prognosis of patients undergoing electrophysiologic studies for syncope of unknown origin". The American Journal of Cardiology. 62 (17): 1186–1191. doi:10.1016/0002-9149(88)90257-3. ISSN 0002-9149.